SC
CORT icon

Stephens Consulting’s Corcept Therapeutics CORT Stock Holding History

Stephens Consulting’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25
Closed -$2.86K – 1371
2025
Q1 		$2.86K Buy
+25
New +$1.52K ﹤0.01% 418

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Stephens Consulting's CORT Position: Q2 2025 in Review

Stephens Consulting sold out of Corcept Therapeutics (CORT) in Q2 2025, closing a stake of 25 shares — an estimated $2.86K sold.

Stephens Consulting first reported a position in CORT in Q1 2025 and held it in 1 quarter. The position peaked at $2.86K in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2025.

  • Stephens Consulting reported no remaining Corcept Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 25 Corcept Therapeutics shares in Q2 2025, an estimated $2.86K.
  • Stephens Consulting first reported a position in Corcept Therapeutics in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's Corcept Therapeutics position peaked at $2.86K in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.